NSE filing, NSE: KOTAKBANK. Summary written from the filing by ALFA Finder's alert engine.
Kotak Mahindra Bank Ltd: key numbers
- Share price
- ₹440.00
- Market cap
- ₹4,37,707 Cr
- Revenue (annual)
- ₹69,781 Cr
- Net profit (annual)
- ₹19,288 Cr
- P/E (TTM)
- 20.4×Sector 19.7×
- Promoter holding
- 25.87%+0.00% QoQ
- FII holding
- 24.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kotak Mahindra Bank Ltd
All →Kotak Mahindra Bank Earnings Call Transcript: Key Takeaways
Kotak delivered strong PAT growth led by a massive FCNR(B) deposit mobilization, which provided significant liquidity for future deployment. Management is prioritizing responsible growth while navigating a rising interest rate environment.
- Call
- Guides 19% growth
Kotak Mahindra Bank Management Change
Kotak Mahindra Bank named Anup Kumar Saha MD & CEO from January 2027. Ashu Suyash re-appointed as Independent Director for three years.
- Execution
- Three years, 1 January 2027 onward (MD & CEO); 24 January 2027 to 23 January 2030 (Independent Director)
Kotak Mahindra Bank Investor Presentation: Key Takeaways
Q2FY27 consolidated PAT ₹5,645 cr (+26% YoY); Bank PAT ₹4,212 cr (+29%). NII +16%, credit cost 0.35% (0.79%), bank ROE 11.65%. Strategy: 'Transforming for scale' via segments, product businesses, tech/AI.
Kotak Mahindra Bank Results Update
Kotak Mahindra Bank's media release reports Q2FY27 standalone PAT of ₹4,212 crore, up 29% YoY. Consolidated PAT rose 26% YoY to ₹5,645 crore.
Kotak Mahindra Bank Financial Results
Kotak Mahindra Bank's board approved unaudited consolidated and standalone results for the quarter and half-year ended September 2026. Joint auditors issued unmodified review conclusions on the statements.
Kotak Mahindra Bank Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.